Comparative study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna(®) and Cyclofem(®)) on lipid and lipoprotein metabolism

Contraception

Volumn 56, Issue 4, 1997, Pages 193-207

  D'Arcangues, C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cyclofem( ); Estradiol cypionate; Estradiol valerate; Injectable contraceptives; Lipid metabolism; Medroxyprogesterone acetate; Mesigyna( ); Norethisterone enanthate

Indexed keywords

APOLIPOPROTEIN A1; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; FEMALE; FOLLICULAR PHASE; HORMONAL CONTRACEPTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LIPID METABOLISM; LUTEAL PHASE; MULTICENTER STUDY; NORMAL HUMAN;

ADULT; CHOLESTEROL; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; LIPIDS; LIPOPROTEINS; LONGITUDINAL STUDIES; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; TRIGLYCERIDES;

EID: 0030707489     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00139-X     Document Type: Article

References (27)

1. World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bull WHO 1993;70:677-89.
2. Newton JR, d'Arcangues C, Hall PE. "Once-a-month" combined injectable contraceptives. J Obstet Gynecol 1994;14(suppl 1):S1-S34.
3. Allain CC, Poon LS, Chan CSG. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
4. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-82.
5. Grove TH. Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate/magnesium. Clin Chem 1979;25:560-4.
6. Assmann G, Jabs HU, Kohnert U, et al. LDL-cholesterol determination in blood following precipitation of LDL with polyvinyl sulfate. Clin Chim Acta 1984;140:77-83.
7. Siedel J, Schiefer S, Rosseneu M, et al. Immunoturbidimetric method for routine determinations of apolipoproteins AI, AII and B in normo-and hyperlipemic sera: comparative evaluation against immunonephelometry. Clin Chem 1988;34:1821-5.
8. Kostner GM. Apolipoproteins and lipoproteins of human plasma: significance in health and in disease. Adv Lipid Res 1983;20:1-43.
9. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-8.
10. Uccella R, Donnini P, Franzetti I, Gaiazzi M. Serum lipid pattern as severity indicator of angiographically assessed coronary artery disease. Artery 1993;20:346-60.
11. La Rosa JC. Dyslipoproteinemia in women and the elderly. Med Clin North Am 1994;78:163-80.
12. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114:413-9.
13. Brunner D, Weisbort J, Meshulam N, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donodo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987;59:1271-6.
14. Jacobs DR, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics' Prevalence Study. Am J Epidemiol 1990;131:32-47.
15. Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16.
16. Amouyel P, Isorez D, Bard JM, et al. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle AI in adolescents. Arterioscler Thromb 1993;13:1640-4.
17. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipids Research Clinics prevalence cohort. Arch Intern Med 1994;154:679-84.
18. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987;36:181-92.
19. Ginsburg KA, Moghissi KS. Alternate delivery systems for contraceptive progestogens. Fertil Steril 1988;49(suppl.)5:16S-30S.
20. Kay CR. The Royal College of General Practitioners' Oral Contraception study: some recent observations. Clin Obstet Gynaecol 1984;11:759-86.
21. Kremer J, de Bruijn HWA, Hindriks FR. Serum high-density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate. Contraception 1980;22:359-67.
22. World Health Organization, Task Force on Long-acting Systemic Agents for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 1993;47:177-91.
23. Oyelola OO. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Contraception 1993;47:445-54.
24. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report, 1991.
25. Fahmy K, Khairy M, Allam G, et al. Effect of depot-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991;44:431-44.
26. Enk L, Landgren B-M, Lindberg U-B, et al. A prospective, one-year study on the effects of two long-acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992;24:85-9.
27. McEwan JA, Griffin M, Fotherby K, Trayner I. Long-term use of depot-norethisterone enanthate: effect on blood lipid fractions. Contraception 1992;46:49-60.